Catalyst Pharmaceuticals (CPRX) is a publicly traded Healthcare sector company. As of May 20, 2026, CPRX trades at $31.05 with a market cap of $3.82B and a P/E ratio of 17.25. CPRX moved -0.03% today. Year to date, CPRX is +34.82%; over the trailing twelve months it is +26.72%. Its 52-week range spans $19.05 to $32.56. Analyst consensus is buy with an average price target of $33.10. Rallies surfaces CPRX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks politician and congressional stock disclosures for CPRX, including purchases, sales, transaction dates, owners, and reported trade amounts when available.
| Metric | Value |
|---|---|
| Price | $31.05 |
| Market Cap | $3.82B |
| P/E Ratio | 17.25 |
| EPS | $1.81 |
| Dividend Yield | 0.00% |
| 52-Week High | $32.56 |
| 52-Week Low | $19.05 |
| Volume | 2.75M |
| Avg Volume | 0 |
| Revenue (TTM) | $596.96M |
| Net Income | $221.32M |
| Gross Margin | 85.96% |
7 analysts cover CPRX: 0 strong buy, 3 buy, 4 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $33.10.